Sobi Unveils Promising Data on Aspaveli and NASP Treatments
STOCKHOLM — Sobi® (STO: SOBI) has announced significant findings to be showcased at ASN Kidney Week 2025, related to the efficacy of Aspaveli/Empaveli in treating C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), as well as new data on the investigational medicine NASP for uncontrolled gout.
The Sobi team will present a mix of one oral and six poster presentations regarding Aspaveli/Empaveli. These presentations will include crucial one-year data that solidifies the sustained effectiveness of the treatment in patients battling C3G and primary IC-MPGN.
According to Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi, "Patients receiving Aspaveli/Empaveli experienced a remarkable reduction in proteinuria, regardless of whether they were taking immunosuppressants or their initial proteinuria levels. One-third of these patients achieved complete remission in proteinuria by week 26, in stark contrast to just 3% for those on placebo, with these trends continuing over the entire year. This indicates a strong potential for Aspaveli/Empaveli to revolutionize treatment for these individuals at risk of kidney failure."
Apart from the findings related to Aspaveli, Sobi will also display data from the NASP study, where results indicated that NASP successfully maintained stable renal function over a six-month duration. A higher percentage of patients experiencing a shift in chronic kidney disease (CKD) stages compared to the placebo group was also noted, especially among patients with uncontrolled gout facing stage 3 CKD. Furthermore, treatments with NASP led to fewer gout-related symptoms and were well tolerated by the participants.
Key Presentations Scheduled for ASN Kidney Week 2025
Here are some highlighted studies that will be presented at ASN Kidney Week 2025:
- Aspaveli/Empaveli (pegcetacoplan): This study provides key insights into the sustained proteinuria reduction in patients for 52 weeks, showcasing outcomes from the Phase 3 VALIANT trial. The study will be presented by Dr. Carla M. Nester.
- Poster Presentation: A deep dive into the enrolment status of adolescents and adults with C3 glomerulopathy or primary IC-MPGN as analyzed in the VALE extension trial.
- VALIANT Subgroup Analysis: It emphasizes that pegcetacoplan maintains proteinuria reduction despite varying immunosuppressant usage, presented in a poster session.
- Pediatric Findings: The findings about pediatric patients who continued to show reduced proteinuria levels leading to stabilized eGFR will highlight the importance of early intervention.
- Clinical Comparisons: An analysis of clinical efficacy between pegcetacoplan and Iptacopan in patients with C3 Glomerulopathy, providing insights into treatment strategies.
- Patient Perspectives: A study illustrating the difficulties faced by patients suffering from C3G and primary IC-MPGN, to enhance understanding of care requirements and unmet needs.
About Aspaveli/Empaveli (pegcetacoplan)
Aspaveli/Empaveli (pegcetacoplan) is a targeted therapy that effectively manages excessive complement system activation, contributing to various serious diseases. Approved as the first treatment option in the U.S. for both C3G and primary IC-MPGN in patients aged 12 and older, it significantly reduces levels of proteinuria. This innovative therapy is also recognized for treating paroxysmal nocturnal hemoglobinuria (PNH) across different regions globally.
The VALIANT Study Overview
The VALIANT Phase 3 trial (NCT05067127) was a robust, multi-center study comprising 124 participants aged 12 and above, investigating the efficacy and safety of Aspaveli/Empaveli. Participants experienced a randomized trial, followed by an open-label phase, ensuring that the active treatment's effects were comprehensively evaluated.
Understanding C3 Glomerulopathy and IC-MPGN
C3 glomerulopathy and IC-MPGN are rare, serious conditions that pose a significant risk for kidney failure. Evidence suggests that excessive C3 deposits indicate inflammation and potential kidney damage. Approximately 50% of affected individuals may face kidney failure within five to ten years, which usually necessitates kidney transplants or dialysis.
About NASP and Uncontrolled Gout
NASP represents an innovative investigational drug aimed at lowering serum uric acid levels, essential for managing uncontrolled gout. With over 8.3 million individuals diagnosed with gout in the U.S., the need for effective treatments becomes increasingly crucial, as ignored symptoms can lead to severe mobility limitations and joint deformities.
Collaboration Between Sobi and Apellis
Sobi has paired with Apellis to leverage global co-development rights for pegcetacoplan, ensuring unique market positions across different regions.
About Sobi
Sobi is a global biopharma enterprise dedicated to innovating solutions for rare diseases, employing around 1,900 professionals worldwide. Sobi trades on Nasdaq Stockholm with a remarkable 2024 revenue exceeding SEK 26 billion.
Frequently Asked Questions
What is the significance of the data presented by Sobi?
The data highlights the effectiveness of Aspaveli/Empaveli in managing serious kidney diseases, showcasing the potential for transformative impacts on patient care.
How does NASP function in treating gout?
NASP combines tolerogenic therapies to lower uric acid levels, thereby reducing the occurrence of gout flares effectively.
What were the findings from the VALIANT study?
The VALIANT study showcased significant reductions in proteinuria among patients using pegcetacoplan, emphasizing its importance as a treatment option.
What challenges do patients with C3 glomerulopathy face?
Patients often grapple with a high risk of kidney failure and may require aggressive treatment approaches due to the disease's severity.
Why is collaboration between Sobi and Apellis important?
The collaboration enables shared expertise and resources, maximizing the therapeutic potential of pegcetacoplan across diverse markets.
